Norges Bank Invests $76.20 Million in Lantheus Holdings, Inc. $LNTH

Norges Bank purchased a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 1,144,955 shares of the medical equipment provider’s stock, valued at approximately $76,197,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Hantz Financial Services Inc. grew its holdings in Lantheus by 412.5% during the third quarter. Hantz Financial Services Inc. now owns 492 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 396 shares during the period. Osterweis Capital Management Inc. acquired a new position in Lantheus during the second quarter worth $36,000. Farther Finance Advisors LLC grew its holdings in Lantheus by 71.4% during the fourth quarter. Farther Finance Advisors LLC now owns 660 shares of the medical equipment provider’s stock worth $44,000 after acquiring an additional 275 shares during the period. Larson Financial Group LLC grew its holdings in Lantheus by 324.5% during the fourth quarter. Larson Financial Group LLC now owns 658 shares of the medical equipment provider’s stock worth $44,000 after acquiring an additional 503 shares during the period. Finally, Caitong International Asset Management Co. Ltd acquired a new position in Lantheus during the third quarter worth $55,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Stock Down 1.8%

LNTH opened at $100.98 on Friday. The business’s fifty day moving average is $88.01 and its two-hundred day moving average is $74.96. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.64 and a current ratio of 2.83. The company has a market cap of $6.57 billion, a price-to-earnings ratio of 24.33 and a beta of -0.03. Lantheus Holdings, Inc. has a one year low of $47.25 and a one year high of $104.00.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings data on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.25 by $0.21. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.The business had revenue of $377.33 million for the quarter, compared to the consensus estimate of $354.48 million. During the same period in the prior year, the business earned $1.53 earnings per share. The business’s revenue was up 1.2% on a year-over-year basis. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Analysts anticipate that Lantheus Holdings, Inc. will post 4.42 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently weighed in on LNTH shares. Mizuho upped their price objective on Lantheus from $100.00 to $115.00 and gave the stock an “outperform” rating in a report on Wednesday, May 27th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Lantheus in a report on Tuesday, May 26th. Wall Street Zen lowered Lantheus from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. JonesTrading lowered Lantheus from a “buy” rating to a “hold” rating in a report on Friday, February 27th. Finally, B. Riley Financial reiterated a “buy” rating on shares of Lantheus in a research report on Friday, May 1st. Eight analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, Lantheus presently has a consensus rating of “Moderate Buy” and an average target price of $101.86.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.